Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease characterized by the gradual loss of upper and lower motor neurons that leads to progressive muscle atrophy and weakness. Edaravone, a free-radical scavenger, was approved as an ALS treatment in 2015 in South Korea...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Jin-Mo, Park, Donghwi, Kim, Hyung-Jun, Park, Jin-Sung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281019/
https://www.ncbi.nlm.nih.gov/pubmed/35836136
http://dx.doi.org/10.1186/s12883-022-02788-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9281019/
https://www.ncbi.nlm.nih.gov/pubmed/35836136
http://dx.doi.org/10.1186/s12883-022-02788-x

Ejemplares similares